Advances in Plasma Cell Dyscrasias

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: 15 August 2024 | Viewed by 865

Special Issue Editors

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
Interests: AL amyloidosis; multiple myeloma; Waldenström’s macroglobulinemia; thrombosis in plasma cell dyscrasias
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
Interests: multiple myeloma; Waldenström’s macroglobulinemia; AL amyloidosis; clinical trials
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
Interests: multiple myeloma; Waldenström’s macroglobulinemia; AL amyloidosis; liver cancer; meta-analysis; immunotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Plasma cell dyscrasias are a biologically and clinically heterogeneous group of diseases primarily characterized by the clonal expansion of plasma cells and monoclonal protein secretion. Significant research advances in the field during the past few years have led to improved outcomes for patients with multiple myeloma, AL amyloidosis and lymphoproliferative disorders such as Waldenström’s macroglobulinemia. The ever-increasing understanding of the molecular mechanisms involved in disease pathogenesis and interactions in the tumor microenvironment have led to improved diagnostics, prognostication and novel agent development. Risk characterization of smoldering multiple myeloma has changed, and treatment initiation has shifted to earlier stages of disease. Minimal residual disease assessment by NGF and NGS has become a surrogate endpoint in clinical trials, and is being increasingly incorporated into clinical practice as it reflects the depth of disease remission and correlates strongly with prognosis for patients with multiple myeloma and AL amyloidosis. In addition to immunomodulatory agents, proteasome inhibitors and anticd38 monoclonal antibodies, novel molecular targets and cellular immunotherapies such as chimeric antigen receptor T cells and/or bispecific antibodies have changed the treatment landscape. Immunotherapy will probably be the next revolution in treatment for plasma cell malignancies. Patients with plasma cell leukemia, POEMs and other rare entities have also benefited from the development of new agents. The goal of this Special Issue is to highlight important advances that have taken place in the diagnosis, management and treatment of plasma cell dyscrasias in recent years, and welcomes all papers that address aspects in these areas.

Dr. Despina Fotiou
Dr. Maria Gavriatopoulou
Dr. Ioannis Ntanasis-Stathopoulos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • multiple myeloma
  • smoldering multiple myeloma
  • AL amyloidosis
  • Waldenström’s macroglobulinemia
  • adoptive T-cell therapies
  • immunotherapy
  • measurable residual disease
  • POEMs
  • plasma cell leukemia

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 298 KiB  
Review
The Role of t(11;14) in Tailoring Treatment Decisions in Multiple Myeloma
Cancers 2023, 15(24), 5829; https://doi.org/10.3390/cancers15245829 - 13 Dec 2023
Viewed by 613
Abstract
Multiple myeloma (MM) represents a hematological neoplasia with an uncontrolled proliferation of malignant plasma cells and complex cytogenetic abnormalities. t(11;14) has emerged as a crucial genetic aberration and is one of the most common primary translocations in MM. Patients harboring t(11;14) represent a [...] Read more.
Multiple myeloma (MM) represents a hematological neoplasia with an uncontrolled proliferation of malignant plasma cells and complex cytogenetic abnormalities. t(11;14) has emerged as a crucial genetic aberration and is one of the most common primary translocations in MM. Patients harboring t(11;14) represent a distinctive subgroup with a clinical profile that differs from t(11;14)-negative MM risk categories. One of the key features linked with t(11;14) is the BCL2 dependency, indicating vulnerability to BCL2 inhibition. BCL2 inhibitors, such as venetoclax, demonstrated impressive efficacy alone or in combination with other anti-myeloma drugs in patients with RRMM accompanied by t(11;14) and BCL2 overexpression. Therefore, t(11;14) plays a key role in both risk stratification and informed decision making towards a tailored therapy. In this review, we highlight the biology of t(11;14) in MM cells, summarize the current evolving role of t(11;14) in the era of novel agents and novel targeted therapies, illuminate current efficacy and safety data of BCL2-based treatment options and explore the future prospects of individualized precision medicine for this special subgroup of patients with MM. Full article
(This article belongs to the Special Issue Advances in Plasma Cell Dyscrasias)

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: Modern diagnostic methods in multiple myelom - focus on Omics
Authors: Novakova, D, Capounova V, Baloga S, Maisnar V, Radocha J
Affiliation: 4th Department of Internal Medicine-Hematology, Faculty of Medicine in Hradec Králové, University Hospital Hradec Kralove, Charles University, 50005 Hradec Kralove, Czech Republic

Back to TopTop